European Medicines Agency budget for 2026

Veterinary medicines European public assessment report (EPAR): Ecovaxxin MS, Mycoplasma synoviae, strain K588A, Live, Status: Authorised

Sixth European Medicines Agency (EMA) and the Association of the European Self-Care Industry (AESGP) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 January 2026, 14:00 (CET) to 23 January 2026, 16:00 (CET)

Seventh European Medicines Agency - EuropaBio bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 20 January 2026, 11:00 (CET) to 20 January 2026, 13:00 (CET)

Human medicines European public assessment report (EPAR): Reagila, cariprazine, Date of authorisation: 13/07/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Xalkori, crizotinib, Date of authorisation: 23/10/2012, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin, Date of authorisation: 23/10/2001, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Date of authorisation: 22/12/2025, Status: Authorised

PSUSA/00000836/202503

Human medicines European public assessment report (EPAR): Cabazitaxel Accord, cabazitaxel, Date of authorisation: 28/08/2020, Revision: 8, Status: Authorised